Physician profile
Joseph E Pavano
NPI 1700851565
$21,616.66
in general payments reported to CMS, 2019-2025
17 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $184 · 2021: $18K · 2022: $1,018 · 2023: $349 · 2024: $735 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $17,355.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $648.97 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $599.31 | 2022-2025 | Miebo, Xiidra |
| Optos, INC. | $545.87 | 2019 | |
| Allergan, INC. | $464.51 | 2019-2022 | |
| Alcon Vision LLC | $383.26 | 2022-2024 | Total30, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $314.52 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $249.25 | 2019-2021 | |
| Shire North American Group INC | $152.36 | 2019 | |
| Rxsight INC | $146.88 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $144.88 | 2023-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $144.02 | 2022 | |
| Spark Therapeutics, INC. | $125.00 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $122.12 | 2024 | Acuvue |
| Abbvie INC. | $116.34 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.08 | 2019 | |
| Horizon Therapeutics Plc | $24.22 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pavano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.